Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7523111 | 0.90 | NUDT1 (0.38) | NUDT1KMT2AMEN1SMN1; SMN2CRHBP | |
| SCHEMBL7521998 | 0.87 | HRH4 (0.43) | NUDT1LMNAKMT2ASMN1; SMN2CRHBP | |
| SCHEMBL6765511 | 0.86 | MEN1 (0.41) | NUDT1LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14269185 | 0.84 | HRH4 (0.36) | NUDT1LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6761125 | 0.82 | NUDT1 (0.52) | NUDT1LMNAKMT2ASMN1; SMN2CRHBP | |
| SCHEMBL6397494 | 0.81 | NUDT1 (0.51) | NUDT1LMNAKMT2ASMN1; SMN2CRHBP | |
| SCHEMBL7512888 | 0.79 | HTT (0.55) | LMNAKMT2AMEN1SMN1; SMN2CRHBP | |
| SCHEMBL9876946 | 0.79 | ALDH1A1 (0.44) | LMNAKMT2AMEN1SMN1; SMN2CYP1A2 | |
| SCHEMBL11189488 | 0.78 | ALDH1A1 (0.43) | NUDT1LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14269186 | 0.78 | BCHE (0.35) | NUDT1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0736300-B1 | Use in a composition of a pyrimidine derivative substituted in position 6 as an activator and/or stabilizer of cyclooxygenase | OREAL (FR) | 2003-03-05 | — | — | EP | claimed |
| US-20020103216-A1 | Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide | PRUCHE FRANCIS (FR) | 2002-08-01 | — | — | US | claimed |
| EP-0829260-B1 | Use of at least one pyrimidine derivative substituted in position 6 as stimulant of tyrosinase | OREAL (FR) | 2002-05-15 | — | — | EP | claimed |
| US-6380263-B1 | ADMINISTERING TO HUMAN EFFECTIVE TYROSINASE ACTIVITY-STIMULATING AMOUNT OF AT LEAST ONE 6-SUBSTITUTED PYRIMIDINE 3-OXIDE COMPOUND FOR PROMOTING PIGMENTATION OF THE SKIN AND/OR HAIR | SOCIETE L'OREAL (FR) | 2002-04-30 | — | — | US | claimed |
| US-5756092-A | DRUGS OR COSMETIC MIXTURE TREATING SKIN DISORDERS, ALOPECIA | SOCIETEL'OREAL S.A. (FR) | 1998-05-26 | — | — | US | claimed |
| EP-0736300-A2 | Use in a composition of a pyrimidine derivative substituted in position 6 as an activator and/or stabilizer of cyclooxygenase | L'OREAL (FR) | 1996-10-09 | — | — | EP | claimed |
| EP-0356271-B1 | 2,4-Diamino-pyrimidine-3-oxide derivatives and their use in the treatment and the prevention of hair drop | OREAL (FR) | 1995-04-05 | — | — | EP | claimed |
| US-4973474-A | 2,4-diaminopyrimidine 3-oxide derivatives and their use for the treatment and prevention of hair loss | L'OREAL (FR) | 1990-11-27 | — | — | US | claimed |
| US-20050049232-A1 | Composition | LINDAU PAR (SE) | 2005-03-03 | — | — | US | disclosed |
| EP-1463483-A1 | NEW COMPOSITION | Ponsus Pharma AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| EP-1002536-B1 | 2-Amino, 4-alkylamino pyrimidine 3-oxydes as soothing agents for the skin | OREAL (FR) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003055454-A1 | NEW COMPOSITION | PONSUS PHARMA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| EP-0736300-B1 | Use in a composition of a pyrimidine derivative substituted in position 6 as an activator and/or stabilizer of cyclooxygenase | OREAL (FR) | 2003-03-05 | — | — | EP | disclosed |
| US-20020103216-A1 | Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide | PRUCHE FRANCIS (FR) | 2002-08-01 | — | — | US | disclosed |
| US-6380263-B1 | ADMINISTERING TO HUMAN EFFECTIVE TYROSINASE ACTIVITY-STIMULATING AMOUNT OF AT LEAST ONE 6-SUBSTITUTED PYRIMIDINE 3-OXIDE COMPOUND FOR PROMOTING PIGMENTATION OF THE SKIN AND/OR HAIR | SOCIETE L'OREAL (FR) | 2002-04-30 | — | — | US | disclosed |
| US-5772990-A | Composition for slowing down the loss of hair based on pyrimidine N-oxides triaminosubstituted or their sulfoconjugated | L'OREAL (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5756092-A | DRUGS OR COSMETIC MIXTURE TREATING SKIN DISORDERS, ALOPECIA | SOCIETEL'OREAL S.A. (FR) | 1998-05-26 | — | — | US | disclosed |
| EP-0736300-A2 | Use in a composition of a pyrimidine derivative substituted in position 6 as an activator and/or stabilizer of cyclooxygenase | L'OREAL (FR) | 1996-10-09 | — | — | EP | disclosed |
| EP-0736300-A2 | Use in a composition of a pyrimidine derivative substituted in position 6 as an activator and/or stabilizer of cyclooxygenase | L'OREAL (FR) | 1996-10-09 | — | — | EP | disclosed |
| US-4973474-A | 2,4-diaminopyrimidine 3-oxide derivatives and their use for the treatment and prevention of hair loss | L'OREAL (FR) | 1990-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103216-A1 | Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide | TYR, TH, MC1R | NUDT1 38/4885LMNA 4571/4885KMT2A 3707/4885 |
| US-20050049232-A1 | Composition | CUTA, LIPG, LIPA | NUDT1 4169/4885LMNA 212/4885KMT2A 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.